MT-ND4 and Leber hereditary optic neuropathy: Duration of disease did not lead to a statistically significant difference in visual acuity changes in LHON patients treated with rAAV2‐ND4 gene therapy (P = 0.271 at 1 month and P = 0.993 at 3 months).